AUTHOR=Brietzke Aline P. , Rozisky Joanna R. , Dussan-Sarria Jairo A. , Deitos Alicia , Laste Gabriela , Hoppe Priscila F. T. , Muller Suzana , Torres Iraci L. S. , Alvares-da-Silva Mário R. , de Amorim Rivadavio F. B. , Fregni Felipe , Caumo Wolnei 

TITLE=Neuroplastic Effects of Transcranial Direct Current Stimulation on Painful Symptoms Reduction in Chronic Hepatitis C: A Phase II Randomized, Double Blind, Sham Controlled Trial

JOURNAL=Frontiers in Neuroscience

VOLUME=9

YEAR=2016

URL=https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2015.00498

DOI=10.3389/fnins.2015.00498

ISSN=1662-453X

ABSTRACT=<p><bold>Introduction:</bold> Pegylated Interferon Alpha (Peg-IFN) in combination with other drugs is the standard treatment for chronic hepatitis C infection (HCV) and is related to severe painful symptoms. The aim of this study was access the efficacy of transcranial direct current stimulation (tDCS) in controlling the painful symptoms related to Peg-IFN side effects.</p><p><bold>Materials and Methods:</bold> In this phase II double-blind trial, twenty eight (<italic>n</italic> = 28) HCV subjects were randomized to receive either 5 consecutive days of active tDCS (<italic>n</italic> = 14) or sham (<italic>n</italic> = 14) during 5 consecutive days with anodal stimulation over the primary motor cortex region using 2 mA for 20 min. The primary outcomes were visual analogue scale (VAS) pain and brain-derived neurotrophic factor (BDNF) serum levels. Secondary outcomes were the pressure-pain threshold (PPT), the Brazilian Profile of Chronic Pain: Screen (B-PCP:S), and drug analgesics use.</p><p><bold>Results:</bold> tDCS reduced the VAS scores (<italic>P</italic> &lt; 0.003), with a mean pain drop of 56% (<italic>p</italic> &lt; 0.001). Furthermore, tDCS was able to enhance BDNF levels (<italic>p</italic> &lt; 0.01). The mean increase was 37.48% in the active group. Finally, tDCS raised PPT (<italic>p</italic> &lt; 0.001) and reduced the B-PCP:S scores and analgesic use (<italic>p</italic> &lt; 0.05).</p><p><bold>Conclusions:</bold> Five sessions of tDCS were effective in reducing the painful symptoms in HCV patients undergoing Peg-IFN treatment. These findings support the efficacy of tDCS as a promising therapeutic tool to improve the tolerance of the side effects related to the use of Peg-IFN. Future larger studies (phase III and IV trials) are needed to confirm the clinical use of the therapeutic effects of tDCS in such condition.</p><p><bold>Trial registration:</bold> Brazilian Human Health Regulator for Research with the approval number CAAE 07802012.0.0000.5327.</p>